Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Terns Pharmaceuticals (TERN) Non-Current Assets (2020 - 2023)

Terns Pharmaceuticals (TERN) has disclosed Non-Current Assets for 4 consecutive years, with $1.2 million as the latest value for Q3 2023.

  • For the quarter ending Q3 2023, Non-Current Assets fell 39.87% year-over-year to $1.2 million, compared with a TTM value of $6.1 million through Sep 2023, down 24.11%, and an annual FY2022 reading of $1.8 million, up 61.49% over the prior year.
  • Non-Current Assets was $1.2 million for Q3 2023 at Terns Pharmaceuticals, down from $1.4 million in the prior quarter.
  • Across five years, Non-Current Assets topped out at $2.6 million in Q1 2022 and bottomed at $1.1 million in Q3 2021.
  • Average Non-Current Assets over 4 years is $1.6 million, with a median of $1.4 million recorded in 2020.
  • The sharpest move saw Non-Current Assets soared 113.34% in 2022, then crashed 39.87% in 2023.
  • Year by year, Non-Current Assets stood at $1.4 million in 2020, then fell by 19.77% to $1.1 million in 2021, then soared by 61.49% to $1.8 million in 2022, then crashed by 33.08% to $1.2 million in 2023.
  • Business Quant data shows Non-Current Assets for TERN at $1.2 million in Q3 2023, $1.4 million in Q2 2023, and $1.6 million in Q1 2023.